The purpose of this study is to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

A phase 2, randomized, double masked clinical, parallel-group clinical trial to evaluate the efficacy and safety of PRO-148 ophthalmic solution compared with SYSTANE ® ophthalmic solution for the treatment of signs and symptoms of mild-to-moderate dry eye syndrome.

Inclusion Criteria:

• Patients with diagnosis of mild-to-moderate drye eye syndrome.
• Male or female patients.
• Patients 18 years of age

Exclusion Criteria:

• Patients with one blind eye.

• Visual acuity of 20/40 in any eye

• Patients with history of active stage of any other concomitant ocular disease.

• Patients taking any medication, topically or by any other route, which could interfere with the study's results, in the 3 days prior to trial or until a time period in which residual effects could be present.

• Contraindications or sensitivity to any component of the study treatments.

• Ocular surgery within the past 3 months.

• Contact lens users.

• Females of childbearing potential )may not participate in the study if any of the following conditions exist:

  • They are pregnant,
  • They are breastfeeding,
  • They have a positive urine pregnancy test at screening,
  • They intend to become pregnant during the study, or
  • They do not agree to use adequate birth control methods for the duration of the study.

• Participation in any studies of investigational drugs within 90 days previous to the inclusion.

Discontinuation criteria:

• Patients could be discontinued before the completion of the study because of adverse events, pregnancy, protocol violations, lack of efficacy, or administrative reasons.